$VSTM

Paterson Dan sold $87K of VSTM

Paterson Dan (President and CEO) sold 20,871 shares of Verastem, Inc. (VSTM) at $4.18 on 2026-06-22 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Paterson Dan
Published Jun 24, 2026, 8:45 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 24, 2026, 8:50 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$VSTM
Neutral
high confidence
Mentioned
$VSTM
Relevance
2/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$VSTMNeutralLow
01

Why it matters

The CEO’s open-market sale reduces insider holdings but does not, by itself, indicate a change in company fundamentals given the stated 10b5-1 plan.

02

Market read

Primarily a sentiment/positioning datapoint; likely insufficient alone to drive a sustained repricing without accompanying operational or financial news.

03

What to watch

Traders may overreact to insider sales; the key differentiator here is the pre-arranged 10b5-1 structure, which usually lowers the signal-to-noise.

Relevance 2/10Novelty 4/10Timing: after-hours/filing timestamp 2026-06-24; reflects 2026-06-22 sale

Background

The article is a SEC Form 4 insider transaction disclosure for Verastem, Inc. (VSTM).

Company-level read

Ticker impact

$VSTMNeutralHigh confidence
Context

Verastem CEO Paterson Dan sold 20,871 shares at $4.18/share under a 10b5-1 plan, disclosed via Form 4 on 2026-06-24.

Expected impact

Low near-term impact; any reaction is likely muted and short-lived unless paired with other new company-specific catalysts.

Evidence & confidence

The filing is a Form 4 insider transaction with explicit 10b5-1 pre-arrangement, which generally reduces interpretive weight for immediate fundamentals.

Market effects

No clear sector read-through; this is company-specific insider liquidity rather than a sector/regulatory shift.

None.

None.

Counterpoint

Because the sale is explicitly under a 10b5-1 plan, it may be more about scheduled diversification/liquidity than bearish expectations.

Key entities

  • Verastem, Inc.

    Subject of the Form 4 insider transaction disclosure.

  • Paterson Dan

    President and CEO who sold shares under a 10b5-1 plan.

Related articles

$VSTMMedAI 8/10

Verastem Oncology Q2 2026 Earnings: Revenue Beats $40.1 Million

Verastem Oncology (Nasdaq: VSTM) reported Q2 2026 results: GAAP EPS -$0.35 and non-GAAP EPS -$0.31, with revenue of $40.1 million. Revenue rose from $2.1 million a year earlier, driven by AVMAPKI FAKZYNJA CO-PACK net product revenue of $25.1 million and a $15.0 million COPIKTRA milestone. Cash and investments were $136.4 million at June 30, 2026.

$VSTMMed

Verastem, Inc. (VSTM): Results of Operations and Financial Condition

Verastem, Inc. (VSTM) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 tm2622452d2_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Verastem Oncology Reports Second Quarter 2026 Financial Results and Highlights Recent Business Updates AVMAPKI® FAKZYNJA® CO-PACK net product revenue of $25.1 million First patients dosed in all three TARGET-D Phase 2 reg

$OFIXMed

These 7 Small Caps Are On Fire In July: Here's Why - ExxonMobil Holdings (NYSE:XOM), Vertex Pharmaceutica

The Russell 2000 stayed near 3,000 with little movement, while seven small-cap stocks gained at least 28% in four sessions. The article cites July surges for Orthofix (OFIX) on CMS reimbursement reversal, REGENXBIO (RGNX) on FDA resubmission alignment and AbbVie milestone, Verastem (VSTM) on short-squeeze setup, ADC Therapeutics (ADCT) rebound, Sable Offshore (SOC) refinancing, Rapid7 (RPD) takeover speculation, and Crinetics (CRNX) surge toward an offer price.

$VSTMMed

Verastem Stock Jumps As Data Shows Strong Survival Trends In Pancreatic Cancer - Verastem (NASDAQ:VSTM)

Verastem (NASDAQ:VSTM) shares rose after updated RAMP 205 pancreatic cancer trial data. The company reported 86% overall survival at six months and 68% progression-free survival at six months; 83% of patients had tumor shrinkage at the recommended phase 2 P2D dose, with no new safety signals. The update also noted 90% metastatic at diagnosis and 9 patients still on treatment.